Abstract
Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines world-wide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca– Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.
Original language | English (US) |
---|---|
Article number | 624 |
Journal | Microorganisms |
Volume | 10 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2022 |
Keywords
- COVID-19 vaccine
- Chilblains
- Delayed hypersensitivity reaction
- Herpes zoster
- MRNA vaccine
- Morbilliform
- Rash
- Skin reaction
- Urticaria
ASJC Scopus subject areas
- Microbiology
- Microbiology (medical)
- Virology